Skip to main content
Premium Trial:

Request an Annual Quote

FivePrime, Pfizer Team on Cancer, Diabetes Research

NEW YORK (GenomeWeb News) – FivePrime Therapeutics said today that it will use its protein library in cell-based assays and in vivo screens to find antibody targets and therapeutic protein candidates for Pfizer.
 
San Francisco-based FivePrime said that it would receive an up-front payment and equity investment from Pfizer and three years of committed research funding. In return, Pfizer gets exclusive worldwide rights to develop and commercialize certain products and targets discovered during the research term. The New York-based drug giant also would pay FivePrime royalties and milestone payments. Further terms and financial details were not disclosed.
 
FivePrime also said that its existing investors made a co-investment in conjunction with Pfizer’s equity purchase, though it did not disclose the details of that investment.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.